A robust, diversified pipeline is advancing with multiple late-stage and next-gen assets targeting high unmet needs in hematology, oncology, and rare diseases. Key data readouts and regulatory milestones are expected over the next 12–24 months, supported by strong financials and strategic collaborations.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.